The QuinteT Recruitment Intervention supported five randomized trials to recruit to target:a mixed-methods evaluation by Rooshenas, Leila et al.
                          Rooshenas, L., By-Band-Sleeve study group, CSAW study group, HAND-1
study group, OPTIMA prelim study group, the Romio feasibility study
group, ... Macpherson, I. E. (2019). The QuinteT Recruitment Intervention
supported five randomized trials to recruit to target: a mixed-methods
evaluation. Journal of Clinical Epidemiology, 106, 108-120.
https://doi.org/10.1016/j.jclinepi.2018.10.004
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1016/j.jclinepi.2018.10.004
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.sciencedirect.com/science/article/pii/S0895435618306280 . Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Journal of Clinical Epidemiology 106 (2019) 108e120ORIGINAL ARTICLE
The QuinteT Recruitment Intervention supported five randomized trials to
recruit to target: a mixed-methods evaluation
Leila Rooshenasa,*,1, Lauren J. Scottb,1, Jane M. Blazebya, Chris A. Rogersa,c, Kate M. Tillinga,
Samantha Husbandsa, Carmel Conefreya, Nicola Millsa, Robert C. Steind, Chris Metcalfea,
Andrew J. Carre, David J. Bearde,f, Tim Davisg, Sangeetha Paramasivana, Marcus Jepsona,
Kerry Averya, Daisy Elliotta, Caroline Wilsona, Jenny L. Donovana,b,1, On behalf of the
By-Band-Sleeve study group, CSAW study group, HAND-1 study group, Optima prelim study
group, the Romio feasibility study group
aPopulation Health Sciences, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, Bristol, United Kingdom
bNIHR Collaboration for Leadership in Applied Health Research and Care at University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
cClinical Trials and Evaluation Unit, Bristol Royal Infirmary, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
dUniversity College London Hospitals (UCLH), Biomedical Research Centre (BMC), University College London Hospitals, 1st Floor Central, 250 Euston
Road, London NW1 2PG, UK
eNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
fRoyal College of Surgeons Surgical Intervention Trials Unit (SITU), University of Oxford, Oxford, United Kingdom
gQueen’s Medical Centre, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham NG7 2UH, UK
Accepted 10 October 2018; Published online 16 October 2018AbstractObjective: To evaluate the impact of the QuinteT Recruitment Intervention (QRI) on recruitment in challenging randomized controlled
trials (RCTs) that have applied the intervention. The QRI aims to understand recruitment difficulties and then implements ‘‘QRI actions’’ to
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Key findings
 The QuinteT Recruitment Intervention (QRI) sup-
ported five challenging randomized controlled tri-
als (RCTs) in surgery/oncology to recruit to
target. The QRI operated by first investigating the
sources of recruitment difficulty in each RCT and
then implementing tailored ‘‘QRI actions’’ to
address the issues as recruitment proceeded.
 Four of the five RCTs encountered recruitment
challenges, underpinned by difficulties in commu-
nicating the trial to potential participants and issues
around approaching eligible patients. These issues
were addressed through QRI actions delivered as
the RCTs were recruiting.
 Randomization rates significantly improved after
QRI action in three trials that encountered commu-
nication difficulties. There was no significant dif-
ference in two RCTs, which both recruited above
target from their outsets and had received previous
QRI support. Two trials that received QRI actions
designed to address issues around approaching pa-
tients saw significant improvements in the numbers
of patients approached per site/month.
What this adds to what was known?
 There is a growing body of empirical research
devoted to explaining why recruitment can be chal-
lenging, but a dearth of effective solutions.
Numerous systematic reviews have repeatedly
highlighted the paucity of broadly applicable,
effective strategies to improve trial recruitment.
This initial evaluation suggests that the QRI can
effectively identify and address recruitment issues,
leading to improvements in recruitment in a range
of RCTs.
What is the implication and what should change
now?
 This evidence provides a platform for trialists to
consider adopting the QRI (or similar approaches)
in their RCTs, particularly if recruitment issues are
anticipated. Future controlled evaluations of the
QRI are needed to build upon this promising
evidence.1. Introduction
High-quality evidence about treatment effectiveness is
crucial for improving patient outcomes and promoting judi-
cial use of resources. Well-conducted randomized controlledtrials (RCTs) can provide this evidence, but one of the
biggest threats to an RCT’s success is suboptimal recruit-
ment. This can compromise a trial’s statistical power, delay
implementation of findings, and lead to costly extensions or
early closure [1,2]. Various guidance and tools (e.g.,
PRECIS-2) are now available to support trial design and
planning [3,4], but only half of RCTs meet their recruitment
targets [5], and recruitment issues remain the top reason for
premature closure [1,6]. The threat of recruitment difficulties
can also discourage important RCTs from being attempted.
There is a growing body of empirical research devoted
to understanding RCT recruitment issues, but a paucity of
effective solutions [7e10]. The little work that has been
conducted has predominantly focused on lessons learned
from previous RCTs [10]. Promising initiatives, such as
the MRC ‘‘Start’’ program and the clinical trials transfor-
mation initiative, aim to empirically test interventions de-
signed to support recruitment [11,12], but interventions
evaluated to date have had a narrow field of application
or emerged as ineffective [8]. There remains an urgent need
for widely applicable interventions to facilitate RCT
recruitment [7,8], particularly for challenging RCTs, such
as those comparing very different approaches to managing
life-changing conditions.
The QuinteT (qualitative research integrated into trials)
Recruitment Intervention (QRI) was designed to optimize
RCT recruitment [13]. It evolved over the course of 2 decades
since its inception in the ProtecT studyda challenging RCT
that randomized men to surgery, radiotherapy, or monitoring
for localized prostate cancer [14,15]. Rather than relying on
fixed strategies, the QRI delivers tailored solutions to improve
recruitment, basedonadetailedunderstandingof trial-specific
challenges. The intervention focuses on how trial information
is communicated to potential participants and seeks to identify
and address other factors that may undermine recruitment
(e.g., difficulties approaching potential participants). The
QRI has been implemented in a growing number of chal-
lenging RCTs [16e20], some of which have now completed
and reported [21e23].
The aim of this study was to evaluate the impact of the
QRI on RCT recruitment. We undertook a mixed-
methods evaluation of all main and pilot RCTs that have
integrated the intervention and completed (or stopped)
recruitment to date. Our primary objective was to inves-
tigate the impact of the QRI on recruitment rates. Sec-
ondary objectives were to explore the QRI’s likely
mechanisms of action and identify opportunities for its
refinement.2. Materials and methods
2.1. Overview of the QRI
The QRI is designed to be integrated with an RCT’s
recruitment plans. It aims to rapidly understand recruitment
110 L. Rooshenas et al. / Journal of Clinical Epidemiology 106 (2019) 108e120issues and then implement solutions to address these while
recruitment is underway. This is achieved through two iter-
ative phases [13]. In brief:
 Phase 1 is a rapid investigation of theRCT’s recruitment
processes using four core data collection processes: (1)
audio-recording appointments where recruiters discuss
the trial with potential participants; (2) interviews with
recruiters and trial management group (TMG) mem-
bers; (3) mapping eligibility and recruitment pathways;
and (4) scrutinizing trial documentation. The findings
from each source are triangulated to determine the key
areas of recruitment difficulty and fed back to the chief
investigator and TMG.
 Phase 2 involves designing and implementing a ‘‘plan
of action’’ to address recruitment difficulties. The
plan comprises one or more ‘‘QRI actions,’’ typically
including confidential feedback for recruiters who
audio-record their appointments, group feedback/
training, written ‘‘Tips and Guidance,’’ and changes
to trial documentation and processes (e.g., patient in-
formation leaflets, recruitment pathways). QuinteT
Recruitment Intervention actions are designed and
delivered collaboratively by the QRI researcher(s)
and the TMG.2.2. Study design and sampling
A mixed-methods evaluation of the QRI was under-
taken, comprising a quantitative before-and-after compari-
son of recruitment rates and a qualitative case study
analysis of each RCT’s recruitment process.
Randomized controlled trials eligible for inclusion
needed to have integrated the full QRI and be closed to
recruitment (or have completed pilot/feasibility stages).
All RCTs that had collaborated with the QuinteT team be-
tween 2005 and 2017 were assessed, and fulfillment (or
not) of each QRI component was recorded by L.R. and
cross-checked by researchers who worked on each RCT
(see Supplementary Information 1).
2.3. Data collection and analysis
2.3.1. Documentary analysis
The documentary analysis was conducted first, to pro-
duce an overview of the recruitment issues identified
through the QRI and the QRI actions implemented to
address these. Each eligible RCT’s protocol, funding appli-
cation, and articles/reports were consulted for information
about the trial and QRI (see Supplementary Information 2).
2.3.2. Quantitative analysis
Recruitment logs maintained by clinical trials units
(CTUs) recorded the number of eligible patients ap-
proached per month, and the number of those who went
on to be randomized, for each site within each RCT. Site-specific data were not available for RCT 4, so total monthly
recruitment figures were used instead. Data from only one
of the two sites in RCT 2 were included because recruit-
ment log information was not available for the other site.
All RCTs recorded the number of patients randomized
per month, apart from RCT 3, which referred to the ‘‘num-
ber of patients consented’’; we therefore used ‘‘consent’’ as
a surrogate for randomization for this trial.
‘‘QuinteT Recruitment Intervention actions’’ were
defined as any initiatives to optimize recruitment that had
been informed by phase 1 QRI findings, including study-
wide actions (e.g., dissemination of written guidance on
how to explain the trial) or site-specific activities (e.g.,
feedback to a recruiter). As the timing and nature of the first
QRI action could differ across sites in a given RCT, patients
approached in the time up to and including the month of the
first ‘‘QRI action’’ (in their trial and site) were considered
part of the ‘‘preintervention’’ period; patients approached in
any month after were part of the ‘‘postintervention’’ period.
In the absence of site-specific data for RCT 4, we conserva-
tively assumed that all QRI actions impacted all sites.
The analysis was conducted by an independent statisti-
cian (L.J.S.) blind to the RCTs’ identities. The analysis plan
was determined before accessing the data. All statistical an-
alyses were performed in Stata 15.1.
Analysis 1 investigated randomization success (whether a
patient who was eligible and approached went on to be ran-
domized). The association between preintervention/postin-
tervention and randomization success was analyzed using a
mixed-effects logistic regression model, with preinterven-
tion/postintervention and trial fitted as fixed effects, and site
as a random effect. Results are presented as odds ratios (ORs)
with associated confidence intervals (CIs). Whether the ef-
fect of preintervention/postintervention differed by trial
was investigated by fitting a ‘‘preintervention/postinterven-
tion by trial’’ interaction term in the model; if the interaction
was significant at the P 5 0.05 level, then results were pre-
sented by trial rather than overall.
Analysis 2 examined the number of patients approached
per site in the preintervention and postintervention periods.
The association between preintervention/postintervention
and the number of patients approached per site/month
was analyzed using a mixed Poisson regression model, with
preintervention/postintervention and trial fitted as fixed ef-
fects, adjusting for the number of months of recruitment at
a site as the exposure, and site fitted as a random effect. Re-
sults were presented as incident rate ratios (IRRs) with
associated CIs. Again, results were presented by trial if
the preintervention/postintervention by trial interaction
was significant at the P 5 0.05 level.
2.3.3. Qualitative analysis
Semistructured interviews were conducted to investigate
how the QRI had been implemented in each RCT as a
means of triangulating the documentary analysis findings.
Interviews also explored trialists’ perceptions of the
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pling approach was used, where RCT TMG members who
had been involved in recruitment were identified and
invited (via email) to participate. Interviews were conduct-
ed between November 2016 and August 2017 via telephone
or in person and audio-recorded with permission. A topic
guide was used to consistently cover topics aligned with
the objectives (Supplementary Information 3). Written con-
sent had already been obtained through the QRIs, and inter-
viewers (L.R. and S.H.) verbally confirmed individuals
were happy to participate.
Interviews were transcribed verbatim and analyzed
through constant comparative approaches adopted from
Grounded Theory [24,25]. This was an iterative process,
involving line-by-line coding of data and arrangement of
codes into themes and subthemes as new data were ob-
tained and previously coded transcripts were revisited.
NVivo (V10, QSR International) was used to organize the
data. Interviews were analyzed by L.R., with a subset
double-coded by a researcher who had not worked on any
of the trials (C.C.). ‘‘Negative’’ cases that appeared to
contradict emerging themes were sought and presented in
the findings where apparent.3. Results
Thirty RCTs were considered for inclusion, with start
dates spanning 2005-2017. Fifteen RCTs were excluded
because they had not finished recruitment at the time of
the evaluation, and 10 were ineligible because they did
not implement the full QRI (see Supplementary
Information 4 for reasons why).
Five RCTs were included in the evaluation. All were
pragmatic, publicly funded trials in UK secondary care
settings, spanning different clinical specialties and
comparing very different treatments, including less/no
treatment (Table 1). Four had integrated the QRI from
the outset due to anticipated recruitment challenges,
and one RCT integrated the QRI partway through, in
response to recruitment difficulties. Figure 1 shows the
timeline for each RCT, including when the QRI started
(initiation of phase 1) and when QRI actions started to
be implemented (phase 2). The timing of the first QRI ac-
tion ranged from month 3 to month 14 of the RCT’s
recruitment period.
Two trials (RCT 2 and RCT 5) had received support from
QuinteT before recruitment started. Randomized controlled
trial 5 received up-front training/guidance, including a
generic presentation on recruitment challenges/solutions at
the trial’s launch, customized ‘‘tips and guidance’’ docu-
ments for explaining the RCT, refinements to patient-facing
literature, and some recruiters had attended a generic
QuinteT recruitment workshop [26]. Randomized controlled
trial 2 recruiters had been exposed to QRI feedback in a pre-
vious trial [27]. This prior support did not fulfill the definitionof ‘‘QRI actions’’ because activities were not informed by
trial-specific investigation of recruitment issues. Therefore,
the periods up to the first ‘‘QRI action’’ were still considered
‘‘preintervention’’ in these trials.
3.1. Recruitment outcomes
All RCTs successfully recruited their target samples.
Four achieved this on time or earlier than planned, without
opening additional sites (RCTs 1, 2, 3, and 5). Randomized
controlled trial 4, which integrated the QRI partway
through its funded period, had an extension and opened
eight additional sites.
3.1.1. Analysis 1: changes in randomization success
Based on pooled data across the RCTs, 307/783 (39%)
of approached eligible patients were randomized before
the first QRI action, compared with 582/1,160 (50.2%) after
(Table 2). The effect of preintervention/postintervention
differed for the individual RCTs (preintervention/postinter-
vention by trial interaction P 5 0.018), and so each trial
was considered individually in the model (Figure 2, panel
1). Randomization success significantly improved after
intervention for RCT 1 (OR 4.55, 95% CI 1.72-12.02),
RCT 3 (OR 1.54, 95% CI 1.12-2.12), and RCT 4 (OR
2.66 (95% CI 1.90-3.72). There was no evidence of a differ-
ence in RCT 2 (OR 1.68, 95% CI 0.58-4.82) and RCT 5
(OR 1.01, 95% CI 0.52-1.97).
3.1.2. Analysis 2: changes in the number of patients ap-
proached per site/month
The pooled data across all RCTs showed that 1.7 pa-
tients were approached per site/month in the preinterven-
tion periods, compared with 1.3 patients per site/month in
the postintervention periods (Table 3). Considering the tri-
als separately (preintervention/postintervention by trial
interaction P ! 0.001; Figure 2, panel 2), the number of
patients approached significantly decreased after interven-
tion in RCT 4 (IRR 0.43, 95% CI 0.37-0.51), did not
change in RCT 1 (IRR 1.10, 95% CI 0.79-1.53) and RCT
2 (IRR 1.04, 95% CI 0.62-1.75), and showed a significant
improvement in RCT 3 (IRR 1.17, 95% CI 1.01-1.36)
and RCT 5 (IRR 1.66, 95% CI 1.21-2.28).
3.2. Recruitment obstacles
Table 4 lists the challenges identified in each RCT.
Recruitment issues fell under two categories:
3.2.1. Issues relating to communicating the trial to
eligible patients
Recruitment to most trials (RCTs 1, 3, 4, and 5) was
undermined through difficulties in explaining the RCT to
potential participants (‘‘communication issues’’). These
included equipoise issues, apparent through recruiters’ dif-
ficulties in articulating uncertainty, and imbalanced
Table 1. Details of the RCTs included in the evaluation
RCT identifier
Feasibility or
main study
Clinical
specialty Trials arms
Number
of sites
Duration of
recruitment
period (mo) Point of QRI integration
RCT 1
(ISRCTN00786323)
Feasibility
(internal
pilot)
Bariatric
surgery
Surgical procedure A
vs Surgical
procedure B
2 20 Outset
RCT 2
(ISRCTN59036820)
Feasibility
(external
pilot)
Surgery for
esophageal
cancer
Surgical procedure A
vs Surgical
procedure B
2a 12 Outset
RCT 3
(ISRCTN42400492)
Feasibility
(external
pilot)
Oncology
(breast
cancer)
Drug treatment vs
‘‘Test-directed’’
drug treatment
35 21 Incorporated into the
RCT protocol from
the outset but began
on month 8 of
recruitment period.
RCT 4
(ISRCTN 33864128
Main Orthopedic
surgery
(shoulders)
Assessment/
monitoring
vs surgery vs
placebo surgery
32 34 Incorporated into the
RCT protocol partway
through the recruitment
period; began in month 8.
RCT 5
(ISRCTN11164292)
Feasibility Orthopedic
surgery
(hands)
Surgical procedure A
vs Surgical
procedure B
3 10 Outset
Abbreviations: RCT, Randomized controlled trial; QRI, QuinteT Recruitment Intervention.
a Although the RCT took place across two sites, only one of these provided screening log data, and thus only one site was included in this
evaluation.
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were conveyed as being superior or more appropriate). Dif-
ficulties addressing patient preferences for particular treat-
ments/approaches were also common, but most problematic
in RCT 1, where the majority (O87%) of patients ap-
proached declined the trial in favor of a preferred treatment.
Audio-recorded appointments revealed a tendency for re-
cruiters to elicit patients’ preferences at the start of the
consultation and then accept these without discussing the
RCT.
More specific issues arose in individual trials, such as
difficulties in articulating trial designs. For example,
RCT 3 randomized patients to routine treatment versus
‘‘test-directed’’ treatment, whereby patients received a
test that was hypothesized to inform their optimal treat-
ment (i.e., ‘‘personalized treatment’’). Patients sometimesop?mize
Fig. 1. Timeline of RCTs, with points of QRI integration and point at which Q
QuinteT Recruitment Intervention.found it difficult to comprehend the distinction between
randomization and ‘‘testing,’’ both of which played a role
in determining final treatment prescribed. Design-related
issues also arose in RCT 4, where surgical recruiters
encountered difficulties in articulating placebo and
nonsurgical arms.
As an exception, RCT 2 revealed few communication is-
sues to address in the preintervention stage; QRI actions
therefore encouraged recruiters to continue their practices,
with some suggestions for additional information provision
geared toward better informing patients.
3.2.2. Issues pertaining to the number of patients
approached
Recruitment pathways varied from one site to another
and were inefficient in some sites, as in RCT 5. InterviewsRI actions were implemented. RCT, Randomized controlled trial; QRI,
Table 2. Numbers and proportions of eligible and approached patients randomized in the preintervention period (before the first QRI action) and
postintervention period, shown for all trials combined and each individual trial
Number of E&A
patients (N )
Number of randomized
patients (n)
Proportion of E&A patients
randomized (n/N )
All RCTs combined
Preintervention period 783 307 39.2%
Postintervention period 1,160 582 50.2%
Period following:
1-2 QRI actions 518 246 47.5%
3-4 QRI actions 237 117 49.4%
5þ QRI actions 405 219 54.1%
RCT 1
Preintervention period 40 5 12.5%
Postintervention period 304 119 39.1%
Period following:
1-2 QRI actions 120 47 39.2%
3-4 QRI actions 61 24 39.3%
5þ QRI actions 123 48 39.0%
RCT 2
Preintervention period 55 22 40.0%
Postintervention period 19 10 52.6%
Period following:
1-2 QRI actions 13 8 61.5%
3-4 QRI actions 6 2 33.3%
5þ QRI actions - - -
RCT 3
Preintervention period 382 164 42.9%
Postintervention period 363 186 51.2%
Period following:
1-2 QRI actions 260 127 48.8%
3-4 QRI actions 103 59 57.3%
5þ QRI actions - - -
RCT 4
Preintervention period 230 80 34.8%
Postintervention period 396 232 58.6%
Period following:
1-2 QRI actions 49 29 59.2%
3-4 QRI actions 65 32 49.2%
5þ QRI actions 282 171 60.6%
RCT 5
Preintervention period 76 36 47.4%
Postintervention period 78 35 44.9%
Period following:
1-2 QRI actions 76 35 46.1%
3-4 QRI actions 2 0 0%
5þ QRI actions - - -
Abbreviations: E&A, eligible and approached; RCT, Randomized controlled trial; QRI, QuinteT Recruitment Intervention.
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some recruiters felt uncomfortable offering the trial to
eligible patients who they felt would be more appropriate
for one treatment over another; this appeared to restrict
the numbers of eligible patients approached.3.3. QRI actions to optimize recruitment
The QRI actions implemented in each RCT are shown in
Table 4. Feedback on recruiters’ communication practices
was at the heart of each trial’s ‘‘plan of action’’ to optimize
recruitment, delivered to individuals or groups of recruiters
Fig. 2. Results of analysis 1 (change in randomization success, prein-
tervention and postintervention) and analysis 2 (changes in the
numbers of patients approached, preintervention and postinterven-
tion). Panel A: Odds ratio of randomization success after the first
QRI action, shown for individual trials. Panel B: Incident rate ratios
(IRR) of eligible and approached (E&A) patients after the first QRI ac-
tion, shown for individual trials. RCT, Randomized controlled trial;
QRI, QuinteT Recruitment Intervention.
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anonymized extracts from recruitment appointments/inter-
views to illuminate difficulties and potential solutions,
focusing on issues around equipoise communication, artic-
ulation of RCT designs, and management of patient prefer-
ences. Group feedback sessions offered opportunities for
peer-to-peer discussion; individual feedback offered more
specific advice, bespoke to a recruiter’s practices.
Study-wide QRI actions to address communication is-
sues were delivered in all RCTs through trial-specific ‘‘tips
and guidance’’ documents. These included recommenda-
tions for structuring consultations and explaining common
concepts (e.g., ‘‘randomization’’). Changes to patient-
facing documentation were also implemented in some
RCTs with a view to conveying equipoise and trial design
more clearly (e.g., RCT 3).
Issues around approaching patients were addressed by
reviewing summaries of screening logs and exploring cases
where eligible patients had not been approached. In RCT 3,hypothetical vignettes were used to prompt discussion
around contentious aspects of the eligibility criteria to
encourage peer-to-peer discussion. The intention here was
to enable recruiters who were less comfortable approaching
patients with certain characteristics to gain reassurance
from peers who were more comfortable [17]. Scrutiny of
patient pathways and suggestions for refining how patients
were identified/approached were also discussed in site-
specific feedback sessions in RCT 5.3.4. Overall impact of QRI actions
Randomization success improved in RCTs 1, 3, and 4,
all of which appeared to be compromised by communica-
tion issues. Communication issues were also apparent in
RCT 5, but there was no difference in randomization suc-
cess (although the trial recruited above target throughout
its duration). There was also no significant improvement
in randomization success in RCT 2, although the documen-
tary analysis indicated that QRI actions encouraged re-
cruiters to maintain their current successful practices.
Randomized controlled trial 2 and RCT 5 recruited above
target throughout and both had been exposed to prior
QuinteT training.
The numbers of patients approached per site/month
improved after intervention inRCTs3 and 5, in linewith docu-
mented strategies designed to address issues around approach-
ing patients. No significant improvements were observed in
the other RCTs, but therewere noQRI actions that specifically
targeted approach issues. The number of eligible patients ap-
proached per site/month significantly decreased in RCT 4.
Informal correspondence with the TMG indicated that fewer
eligible patients were being identified in the later stages of this
trial, reportedly due to depletion of prevalent cases. The qual-
itative interviews also indicated that the new centers opened
during the postintervention period did not engage as well as
original centers, which diluted the number of patients ap-
proached per site/month.3.5. Trialists’ perspectives on the QRI
Seven trial investigators representing all five RCTs
participated in interviews. Their accounts of the QRI activ-
ities generally complemented the documentary data. The
one exception to this was RCT 2. Although the documenta-
tion indicated that the mandatory components of the QRI
had been conducted, interviews suggested that the QRI
was not fully implemented as it was not deemed necessary
(following observation of successful recruitment trends).
Randomized controlled trial 2 did not have a dedicated
QRI researcher, and the QRI activities were not conducted
intensively. This was corroborated by researchers who
contributed to RCT 2’s QRI, both of whom questioned
whether RCT 2 was eligible for the evaluation. Informants’
accounts from other trials indicated that the QRI had been
delivered as reported in the documentary sources.
Table 3. Average number of patients eligible and approached per site
per month in the preintervention and postintervention period for
each RCT and for all RCTs combined
Number of
site mo
Number of
E&A
patients
Average
number of
E&A patients
(per site per mo)
All RCTs combined
Preintervention period 453 783 1.7
Postintervention period 900 1,160 1.3
RCT 1
Preintervention period 4 40 10
Postintervention period 33 304 9.2
RCT 2a
Preintervention period 9 55 6.1
Postintervention period 3 19 6.3
RCT 3
Preintervention period 265 382 1.4
Postintervention period 227 363 1.6
RCT 4
Preintervention period 157 230 1.5
Postintervention period 626 396 0.6
RCT 5
Preintervention period 18 76 4.2
Postintervention period 11 78 7.1
Abbreviations: RCT, Randomized controlled trial; E&A, eligible
and approached.
a Site data available from one of the 2 recruiting sites.
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of quantifying the impact of the QRI but most felt that
QRI actions translated into improved recruitment (Web
Appendix 1). Most discussed how the QRI had introduced
them to sources of difficulty that they had previously been
unaware of, and those with direct experience of recruiting
gave specific examples of how the QRI had changed their
discussions with patients. Individual/group feedback and
written guidance were thought to have catalyzed these
changes:
Investigator 4: In the very early days, I was a very poor
recruiter. [.]... And actually I learnt from [the QRI], and
the work [QRI researcher] did. Because toward the end I
was much more successful, and I had really started to
follow the guidance in the tips document. And I think it
was extremely useful.
Investigator 5: The problem-solving nature of it was just
a different level of consideration on what the issues were.
[.] No questioneno question [in response to being asked
if they felt the QRI had an impact]. So this language that
I’m speaking now is a direct result of that thinking. I don’t
think we’d delineated it to the same extent then at all. It
seems very straight forward and obvious now [.]dbut this
was a completely different world to us. We were just clini-
cians in a clinic, saying ‘‘there’s a trial here [.]ddo you
want to go in it?’’ [.] I expected, in the beginning, I’ll behonestdI expected ‘‘We’ll do all this talk and it won’t
make a difference’’dbut it did make a difference.
One informant stood apart, having indicated that the
feedback of QRI findings had not been ‘‘surprising,’’
although still mentioned specific issues that had compro-
mised recruitment in sites other than their own:
Investigator 9: There’s nothing that came as a surprise,
but I think it was good. I mean, I think it had an impact.
I think recruitment suddenly improved somewhere else.
Interviewer: In what way do you think?
Investigator 9: Well, I think people realized that they
were overselling [treatment x] and didn’t realize. [Later]
But if we get [another study], I think it’s very important
to have it [QRI] at centers.
Several informants highlighted the necessity for chief in-
vestigators, CTUs, and recruiters to engage with the QRI
and for its processes to be integrated with the trial to facil-
itate success:
Investigator 5: The key thing for me was getting the
chief investigator and the team around them engaged with
it. It will never work if the chief investigator doesn’t get it.
Some questioned whether QRI actions had reached all
sites, particularly those less engaged with the RCT, but
there were also suggestions that feedback/training was un-
likely to be restricted to sites the QRI team directly worked
with (Web Appendix 2). When asked to summarize their
impressions of what the QRI entailed, most emphasized
the feedback/training elements, informed by audio-
recordings of recruiters’ actual practices. Informants tended
to discuss the QRI as a ‘‘complex intervention,’’ hesitating
to pin-point any one aspect that was more effective than
another:
Investigator 5: The whole is greater than the sum of its
parts.
Investigator 2: I wouldn’t want to put it down to one
particular thing. I think it was a combination of things that
had an effect. [.] I think it’s much better if it’s integrated
into the whole structure.4. Discussion
This article reports the first empirical evaluation of the
QRIdan intervention designed to optimize recruitment in
challenging RCTs. The QRI’s impact on recruitment was
examined in five RCTs from oncology and surgical spe-
cialties. The QRI identified issues that appeared to under-
mine recruitment to most of the RCTs, particularly in
relation to how the RCT was communicated to patients.
QuinteT Recruitment Intervention actions sought to address
these difficulties through feedback/training, dissemination
of written guidance, and changes to patient-facing docu-
mentation. There was evidence of improvement in random-
ization success after intervention in three RCTs; the two
RCTs that did not see an improvement both recruited above
target throughout their durations (and had received up-
Table 4. Summary of key sources of recruitment difficulty based on phase 1 findings and timing/type of QRI actions to address difficulties
RCT identifier
Key sources of recruitment difficulties to
emerge from phase 1 investigation
Timing (recruitment mo) and type of
phase 2 QRI actions
RCT 1 1) Difficulties integrating the RCT into existing clinical service:
a Complex recruitment pathways (from point of identifying
eligible patients to the recruitment appointment)
b Structure of consultations was often not conducive to ex-
plaining the RCT rationale; RCT participation was not pre-
sented as a viable option.2) Difficulties conveying equipoise
when describing trial arms to patients
3) Tendency to accept patient preferences, without exploration
4) Difficulties articulating and explaining trial concepts (e.g.,
‘‘randomization’’)
 Month 3: individual feedback for site 1
 Month 4: group feedback for site 1
 Month 7: individual feedback for site 1
 Month 8: group feedback for site 1
 Month 9: individual feedback for site 2
 Month 11: individual feedback for site 1
 Month 13: individual feedback for site 2
 Month 14: individual feedback for site 2
 Month 16: ‘‘Tips and guidance’’ document
circulated to all sites
 Month 18: individual feedback for site 1
 Month 18: Research nurse training event (both
sites)
RCT 2 Recruitment was perceived to be progressing well throughout,
and recruiters were encouraged to continue their practices.
Additional tips were provided in relation to:
1) Conveying equipoise during recruitment appointments
(when describing trial arms)
2) Explaining trial concepts (e.g., ‘‘randomization’’ and
‘‘blinding’’)
3) Addressing patient preferences
 Month 8: Group feedback for site 2
 Month 9: Individual feedback for 2 recruiters in
site 1
 Month 11: Group feedback for site 1 (clinicians)
 Month 11: ‘‘Tips and guidance’’ document
circulated to all sites
RCT 3 1) Clinicians’ discomfort approaching the full spectrum of
eligible patients (clinicians’ individual sense of equipoise).
2) Clinicians’ and research nurses’ discomfort around
introducing the study, based on assumptions that patients
would not be able to process the offer of trial participation.
3) Structure of consultations was not conducive to explaining
the RCT rationale; RCT participation was not presented as a
viable option.
4) Difficulties articulating uncertainty and conveying equipoise
during recruitment appointments
5) Difficulties explaining the trial design clearly
6) Tendency to accept patient preferences, without exploration
7) Difficulties articulating and explaining trial concepts (e.g.,
‘‘randomization’’ and ‘‘blinding’’)
 Month 14: ‘‘Tips and guidance’’ document
circulated to all sites
 Month 15: Edited patient information leaflet
circulated to all sites
 Month 15: Group feedback presented to region 1
(attended by five sites).
 Month 17: Group feedback presented to region 2
sites, with discussion of hypothetical vignettes
(attended by seven sites)
 Month 18: Individual feedback provided for
recruiter from one site
 Month 19: Individual feedback provided for re-
cruiters from 3 sites
 Month 19: Group feedback to two sites.
RCT 4 1) Difficulties articulating and explaining the trial treatments/
management approaches
2) Difficulties conveying equipoise during recruitment
appointments (when describing trial arms)
3) Difficulties explaining the trial design
4) Tendency to accept patient preferences, without exploration
 Month 13: Individual feedback
 Month 14: Individual feedback
 Month 15: ‘‘Tips and guidance’’ in study-wide
newsletter
 Month 16: Study-wide group feedback, attended
by 15 sites
 Month 16: Site visit to provide recruitment
training (one site)
 Month 17: Site visits to provide recruitment
training (two sites)
 Month 22: Site visits to provide recruitment
training (two sites)
 Month 22: ‘‘Tips and guidance’’ document
circulated to all sites
RCT 5 1) Complex recruitment pathways (from point of identifying
eligible patients to the recruitment appointment)
2) Discomfort approaching the full spectrum of eligible
patients (equipoise difficulties).
3) Difficulties conveying equipoise during recruitment
appointments (when describing trial arms)
4) Tendency to accept patient preferences, without exploration
 Month 6: Site-specific group feedback delivered
to sites 1 and 2
 Month 6: Individual feedback provided to re-
cruiters in sites 1 and 2.
 Month 7: Adapted ‘‘tips and guidance’’ document
sent to site 3.
 Month 9: Individual feedback to recruiter in
site 2.
 Month 10: Visit to site 2 to provide training for
new recruiters
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fied issues around approaching eligible patients in some
RCTs, resulting in QRI actions designed to improve oppor-
tunities for approaching patients. The numbers of eligible
patients approached per site/month significantly increased
in two trials that specifically implemented these QRI ac-
tions. The number of patients approached did not change,
or significantly decreased, in the postintervention periods
of other RCTs without these QRI actions. Trialists
perceived a change in recruitment practices after QRI ac-
tions, particularly in relation to how they communicated
with patients, with most reporting that the QRI had un-
earthed issues they had not previously considered. Full inte-
gration of the QRI into the RCTs, with support from chief
investigators and CTUs, was deemed integral to the QRI’s
success.
The study had several limitations. We cannot establish
cause-effect relationships between QRI actions and recruit-
ment and cannot account for other factors that might have ex-
plained changes observed. Tominimize these limitations, we
examined preintervention/postintervention periods at the
level of each site within each trial, rather than defining blan-
ket preintervention/postintervention cutoff periods at the
overall trial level. The improvements in randomization suc-
cess inmultiple RCTs support the notion that theQRI actions
were genuinely influencing and changing recruitment,
although it is possible that recruiters naturally improved their
practices over time. The changes observed are unlikely to be
due to spontaneous improvements, given that the QRI identi-
fied issues that recruiters were not aware of. Furthermore,
QRI actions (and improvements) occurred more than 1 year
into the recruitment periods of some RCTs, by which point
recruiters’ practices had likely stabilized.
The evaluation was only undertaken with five UK RCTs
and thus would be strengthened by inclusion of more trials
spanning a diversity of settings. There were also limitations
in the quality and completeness of data available, leading to
several a priori assumptions. We assumed that QRI actions
affected all recruiters in any given site, and that all sites and
recruiters had been exposed to every ‘‘study-wide’’ QRI ac-
tion (e.g., ‘‘tips and guidance’’ documents). The large RCTs
had many centers that never directly engaged with the QRI,
but we counted their recruitment activity as ‘‘postinterven-
tion’’ following any study-wide QRI actions. These limita-
tions are likely to have resulted in a more conservative
estimate of QRI impact, as recruiters not truly exposed to
QRI actions may have diluted the ‘‘postintervention’’ ef-
fect. The qualitative evaluation was limited by the possibil-
ity that informants’ responses were influenced by
knowledge that the interviewer was affiliated with QRI re-
searchers who worked on their trials. As such, the inter-
views primarily focused on examining how the QRI
operated in each RCT, rather than trialists’ perceived value
of the QRI.
Strengths of the study included the use of mixed
methods, which allowed for a detailed understanding ofwhether (and how) the QRI was likely to have impacted
recruitment. The independent documentary analysis and
qualitative interviews triangulated our understanding of
the potential mechanisms of change in each RCT, and thus
plausibility of effect.
The QRI has previously been recognized as a promising
intervention, in a field that is largely devoid of effective solu-
tions to addressing recruitment issues [28e30]. When faced
with the pressures of improving recruitment, trialists often try
multiple strategies concurrently, making evaluation difficult.
Randomized evaluations have tended to test relatively simple
interventions, such as altering patient information materials
or arranging site visits [31e36]. These have largely been
shown to have little impact on recruitment, although
increasing patients’ knowledge about the clinical condition,
telephone reminders, monetary incentives, and ‘‘opt out’’
processes can be effective [7,8]. However, most of these stra-
tegies are unlikely to improve recruitment in complex trials
involving life-changing conditions or very different interven-
tions, as considered in this evaluation.
The extensive literature on reasons for poor recruitment
supports plausible mechanisms of action for the QRI. Re-
cruiters can experience complex intellectual challenges,
relating to struggles with equipoise, role conflict, and con-
cerns about their relationships with patients [37e39]. Retro-
spective analyses of reasons for trial failure have also
indicated that most issues are ‘‘preventable,’’ with recruiters’
and patients’ preconceptions about treatments frequently un-
derpinning reasons for discontinuation [40]. The QRI recog-
nizes that recruiters’ attitudes, beliefs, and skills can
undermine recruitment at several stages from identifying
eligible patients through to approaching them and presenting
the option of trial participation. Although not exclusively a
‘‘recruiter-targeted’’ intervention, most QRI actions are
geared toward altering recruiters’ practices through guidance
and feedback. Other ‘‘recruiter-targeted’’ interventions have
taken the form of one-off training [41], although those that
have shown positive effects have been context specific
[42,43]. Similar to the QRI, one potentially transferable
initiative trained recruiters to elicit and respond to patients’
views about trial participation; this appeared to be associated
with recruitment successwhen evaluated in a single trial [44].
The theoretical and empirical literature on clinicians’
learning underlines the importance of specific, preplanned,
data-driven feedback [45,46]. In particular, cognitive
learning theory proposes that individuals learn by organizing
and relating new information to existing knowledge, with
feedback presented as one way of achieving this [47].
Application of the QRI to a growing number of RCTs has
provided opportunities to identify common recruitment is-
sues [37,38,48,49] and design pre-emptive training [26].
Randomized controlled trials that have most recently inte-
grated the QRI have included up-front training/guidance,
as in RCT 5, which did not see a significant improvement
in randomization success, although the numbers of patients
approached per site/month increased following QRI actions
118 L. Rooshenas et al. / Journal of Clinical Epidemiology 106 (2019) 108e120designed to address issues around approaching patients. It is
possible that the up-front training may have enhanced
recruitment in the ‘‘preintervention’’ period, or RCT 5 might
have recruited well without the QRI. Randomized controlled
trial 2, which had prior exposure to QRI actions, also re-
cruited above target with no notable issues. Further work
is required to investigate the role of up-front generic training
versus responsive feedback and any sustainable effects of
QRI feedback. Prerecruitment training might address some
generic issues (e.g., suggestions for explaining randomiza-
tion) but is unlikely to address more complex challenges
such as equipoise communication, which can be disrupted
by trial-specific contextual factors.
Future evaluations of the QRI need to include individual
recruiter-level data. Examination of the cost-effectiveness of
the QRI would also be valuable, given that the QRI requires
time and resources (although likely to be small relative to
the costs associated with suboptimal recruitment) [13] and
should consider the transferability of QRI feedback/training
to other RCTs. Ideally, future evaluations of the QRI should
incorporate randomization. Randomizing sites in a given
RCT to receive the QRI (or no QRI) would be challenging
due to the ‘‘ripple effect’’ of QRI actions and cross-site
contamination. Randomization could occur at the RCT level,
although this would be practically difficult and require large
numbers of trials. Despite these complications, the prom-
ising evidence needs to be substantiated by future more
robust evaluations of the QRI and its components.5. Conclusion
The QRI supported recruitment in five challenging RCTs,
all of which successfully achieved their recruitment targets.
There was strong evidence that QRI actions improved
randomization success in the RCTs, with the exception of
two RCTs that had received prerecruitment QRI training/
support, which recruited well from the outset. Improvement
in the number of eligible patients approached was also
apparent in two RCTs where these issues were specifically
addressed. Tailored feedback to recruiters was at the heart
of the QRI actions and was perceived by recruiters to have
had an impact on their practices. While more robust evalua-
tion is required, there is evidence that the QRI has a positive
effect on recruitment in a range of RCTs.Acknowledgments
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